title: Starc II, a multicenter randomized placebo-controlled double-blind clinical trial of trapidil for 1-year clinical events and angiographic restenosis reduction after coronary angioplasty and stenting.
abstract: The objective of this study was to investigate the effect of trapidil 200 mg t.i.d. in preventing the occurrence of death, of myocardial infarction and the need for repeat revascularization at 12 months after balloon PTCA with or without stenting. Coronary restenosis after stenting is still a major drawback of percutaneous coronary interventions (PCI) for 30-40% of patients. Trapidil has been shown to prevent restenosis after PTCA. Eligible patients were randomized to placebo or oral trapidil 200 mg t.i.d. at least 48 hr before PCI and continuing 6 months after a successful balloon angioplasty or stent implantation. Aspirin was given to all patients, and ticlopidine 250 mg b.i.d. to those who received a stent for 4 weeks. In a randomized subgroup of 216 patients, quantitative coronary angiography was performed also at 6-month follow-up. Out of the 933 patients enrolled, primary endpoint incidence was 20.3% in trapidil and 18.0% in placebo (P = 0.37). When recurrence or deterioration of angina was added to the combined endpoint, incidence was 27.4% in trapidil and 23.0% in placebo (P = 0.12). Restenosis rate in patients with 6-month angiography was 25.0% in trapidil arm vs. 30.1% in placebo (P = 0.43). Stent restenosis rate was similar in patients randomized to trapidil or placebo (30.2% vs. 23.8%, respectively; P = 0.44), while in patients treated with balloon angioplasty, it was lower in trapidil (17.1%) than in placebo (40.0%; P = 0.03). Oral trapidil 200 mg t.i.d. for 6 months in addition to aspirin did not influence the occurrence of major cardiac events after coronary angioplasty with or without stenting. In a prespecified subgroup of 191 patients treated with balloon angioplasty only, trapidil reduced angiographic restenosis.
authors.affiliation: Division of Cardiology, Ospedale "S. Maria delle Croci," Ravenna, Italy. ra.hocardio@ausl.ra.it
authors.forename: Aleardo
authors.initials: A
authors.lastname: Maresta
authors.forename: M
authors.initials: M
authors.lastname: Balducelli
authors.forename: R
authors.initials: R
authors.lastname: Latini
authors.forename: G
authors.initials: G
authors.lastname: Bernardi
authors.forename: T
authors.initials: T
authors.lastname: Moccetti
authors.forename: C
authors.initials: C
authors.lastname: Sosa
authors.forename: S
authors.initials: S
authors.lastname: Barlera
authors.forename: E
authors.initials: E
authors.lastname: Varani
authors.forename: E E
authors.initials: EE
authors.lastname: Ribeiro da Silva
authors.forename: A
authors.initials: A
authors.lastname: Monici Preti
authors.forename: A P
authors.initials: AP
authors.lastname: Maggioni
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects*; D001241:Aspirin / Q000627:therapeutic use; D019917:Blood Vessel Prosthesis Implantation / Q000009:adverse effects / Q000295:instrumentation*; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000000981:diagnostic imaging / Q000453:epidemiology / Q000517:prevention & control*; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000000981:diagnostic imaging / Q000628:therapy; D010349:Patient Compliance; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D012449:Safety; D015607:Stents; D013988:Ticlopidine / Q000627:therapeutic use; D014192:Trapidil / Q000627:therapeutic use*; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D014192:Trapidil; D013988:Ticlopidine; D001241:Aspirin